OptimizeRx (NASDAQ:OPRX) and EVO Payments (NASDAQ:EVOP) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.
Risk & Volatility
OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, EVO Payments has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
Insider & Institutional Ownership
58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 52.7% of EVO Payments shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 51.0% of EVO Payments shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for OptimizeRx and EVO Payments, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
OptimizeRx | 0 | 0 | 3 | 0 | 3.00 |
EVO Payments | 0 | 5 | 3 | 0 | 2.38 |
OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. EVO Payments has a consensus target price of $24.00, indicating a potential downside of 12.70%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than EVO Payments.
Profitability
This table compares OptimizeRx and EVO Payments' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
OptimizeRx | -23.79% | -14.44% | -11.49% |
EVO Payments | -1.37% | -6.43% | 2.97% |
Valuation & Earnings
This table compares OptimizeRx and EVO Payments' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
OptimizeRx | $24.60 million | 24.28 | $-3,140,000.00 | ($0.19) | -208.11 |
EVO Payments | $485.78 million | 4.68 | $-10,100,000.00 | $0.66 | 41.65 |
OptimizeRx has higher earnings, but lower revenue than EVO Payments. OptimizeRx is trading at a lower price-to-earnings ratio than EVO Payments, indicating that it is currently the more affordable of the two stocks.
Summary
EVO Payments beats OptimizeRx on 7 of the 13 factors compared between the two stocks.